Skip to content
OpenCapital
Get started

Castle Biosciences CSTL Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

NeoGenomics logo
NeoGenomicsNEO
——

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's share based compensation arrangement by share based payment award options exercisable number?
Castle Biosciences (CSTL) reported share based compensation arrangement by share based payment award options exercisable number of $2.74M in Q1 2026.
How has Castle Biosciences's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?
Castle Biosciences's share based compensation arrangement by share based payment award options exercisable number decreased by 3.7% year-over-year, from $2.85M to $2.74M.